In addition, PharmaEssentia's board of directors today resolved to establish a second subsidiary in Puerto Rico, USA. This move aligns with the multi-tiered legal entity structures and functional division models commonly adopted by large international pharmaceutical companies, such as separating R&D, manufacturing, sales, and asset holding, which helps enhance overall operational efficiency and flexibility.
PharmaEssentia stated that in 2024, it signed a commercial licensing agreement with FORUS for its new drug Ropeg in Canada. FORUS has long been deeply involved in the Canadian hematology and oncology treatment fields, with an experienced management team in drug registration and commercial operations, and has established market channels and cooperation networks, leading to significant collaborative achievements.
Before obtaining Canadian drug approval, Ropeg was included in Health Canada's 'Special Access Program' in Q1 2025, reflecting strong local market demand for Ropeg. FORUS also submitted an application for Ropeg for Polycythemia Vera (PV) in Canada in July 2025, with approval expected in Q3 this year. Applications for the new indication, Essential Thrombocythemia (ET), are also being prepared for submission, further expanding market potential.
PharmaEssentia stated that the acquisition of 100% of FORUS's shares is based on long-term strategic development considerations. After comprehensively evaluating FORUS's operational performance, growth potential, and professional valuation results, the decision was made to proceed with this equity acquisition. This will allow for the full integration of regulatory affairs, marketing, and sales channel resources in Canada, comprehensively strengthening Ropeg and subsequent products' competitive advantages and accelerating their commercialization process in the local market. (Edited by Yang Kai-xiang) 1150409
FACT BOX
- Source: CNA (Central News Agency)
- Category: M&A